

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> A01N 1/00, A61M 1/14, 37/00 A61L 33/00, C08J 7/04	<b>A1</b>	<b>(11) International Publication Number:</b> WO 91/15952 <b>(43) International Publication Date:</b> 31 October 1991 (31.10.91)
<b>(21) International Application Number:</b> PCT/US91/02415 <b>(22) International Filing Date:</b> 9 April 1991 (09.04.91)  <b>(30) Priority data:</b> 509,063 12 April 1990 (12.04.90) US  <b>(71) Applicant:</b> CARDIOPULMONICS, INC. [US/US]; 5060 West Amelia Earhart Drive, Salt Lake City, UT 84116 (US).  <b>(72) Inventors:</b> WINTERS, Suzanne ; 637 2nd Avenue, Salt Lake City, UT 84103 (US). SOLEN, Kenneth, A. ; 536 East 500 South, Orem, UT 84058 (US). SANDERS, Clifton, G. ; 633 East 200 South, Apt. #1, Salt Lake City, UT 84102 (US). MORTENSEN, J., D. ; 10600 Dimple Dell Road, Sandy, UT 84092 (US). BERRY, Gaylord ; 1896 Vine Street, Salt Lake City, UT 84121 (US).	<b>(74) Agents:</b> NYDEGGER, Rick, D. et al.; Workman, Nydegger & Jensen, 1000 Eagle Gate Tower, 60 East South Temple, Salt Lake City, UT 84111 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> GAS PERMEABLE THROMBO-RESISTANT COATINGS AND METHODS OF MANUFACTURE  <b>(57) Abstract</b> <p>The present invention is directed to thrombo-resistant coatings for use with gas permeable biomedical devices and implants. The coatings include a <u>siloxane surface</u> onto which a plurality of amine functional groups have been bonded. Covalently bonded to the amine functional groups are a plurality of poly(ethylene oxide) chains, such that a single poly(ethylene oxide) chain is bonded to a single amine functional group. A quantity of at least one bioactive molecule designed to counteract a specific blood-material incompatibility reaction is covalently bonded to the poly(ethylene oxide) chains, such that a single bioactive molecule is coupled to a single polyethylene oxide chain. The methods of manufacturing the present invention include preparing a material having a siloxane surface onto which a plurality of amine functional groups have been bonded. This is preferably achieved by plasma etching with ammonia gas. The amine-containing siloxane surface is reacted with poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine groups on the siloxane surface. The material is then reacted with a solution of at least one bioactive molecule which counteracts a blood-material incompatibility reaction, such that a single bioactive molecule is coupled to a single poly(ethylene oxide) chain. The resulting siloxane surface is capable of resisting blood-material incompatibility reactions while maintaining high gas permeability.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

1

**GAS PERMEABLE THROMBO-RESISTANT  
COATINGS AND METHODS OF MANUFACTURE**

BACKGROUND

5

1. The Field of the Invention

The invention relates to thrombo-resistant compositions for coating gas permeable polymers and to the methods of manufacturing such coatings so that the resulting product remains gas permeable and thrombo-resistant. More particularly, the present invention immobilizes at least one bioactive molecule, such as heparin, to a gas permeable siloxane surface in order to combat at least one blood-material incompatibility reaction.

15

2. The Prior Art

Over the years, a large number of medical devices have been developed which contact blood. The degree of blood contact varies with the device and its use in the body. For instance, catheters may briefly contact the blood, while implants, such as heart valves and vascular grafts, may contact blood for a number of years. Regardless of the device, blood contact with foreign materials initiates the process of thrombosis, which may be followed by formation of thromboemboli.

25

Adsorption of proteins is one of the first events to occur when blood contacts a foreign surface. The compositions and conformation of adsorbed proteins influence subsequent cellular responses such as platelet adhesion, aggregation, secretion, complement activation, and ultimately, the formation of cross-linked fibrin and thrombus. Thrombus formation is an obvious and potentially debilitating response to foreign material in contact with blood.

35

1

The initial protein layer at the blood-material interface is subject to denaturation, replacement, and further reaction with blood components. During this phase of protein adsorption, adsorbed fibrinogen is converted to fibrin. Fibrin formation is accompanied by the adherence of platelets and possibly leucocytes. The platelets become activated and release the contents of their granules. This activates other platelets, thereby resulting in platelet aggregation.

10

A thrombus eventually forms from entrapment of erythrocytes (red blood cells) and other blood constituents in the growing fibrin network. Thrombus growth can eventually lead to partial or even total blockage of the vascular channel and/or interference with the function of the device unless the thrombus is sheared off or otherwise released from the foreign surface as an embolus. Unfortunately, such emboli can be as dangerous as blockage of the vascular channel since emboli can travel through the bloodstream, lodge in vital organs, and cause infarction of tissues. Infarction of the heart, lungs, or brain, for example, can be fatal. Therefore, the degree to which the foreign material inhibits thrombus formation, embolization, and protein denaturation is a determinant of its usefulness as a biomaterial.

20

25

In the past, the thrombogenicity of biomedical implants has been treated by the administration of systemic anticoagulants such as heparin and warfarin. However, long-term anticoagulation therapy is not advisable due to the risk of hazardous side effects. Moreover, overdose of anticoagulants may cause lethal side reactions, such as visceral or cerebral bleeding. For these reasons, there have been extensive efforts to develop materials which can be used in biomedical devices or implants which can contact

30

35

1 blood with minimal or no systemic anticoagulation therapy  
being necessary to avoid thrombus formation.

Many studies have attempted to produce a nonthrom-  
5 bogenic blood-contacting surface through immobilization of  
biologically active molecules onto the surface. Such  
bioactive molecules counteract various blood-material  
incompatibility reactions.

Surface modification of polymeric materials offers the  
10 advantage of optimizing the chemical nature of the  
blood/polymer interface while allowing a choice of the  
substrate to be based upon the necessary mechanical  
properties of the blood-contacting device.

The methods used to immobilize bioactive molecules  
15 onto blood-contacting surfaces fall into four general  
groups: physical adsorption, physical entrapment,  
electrostatic attraction, and covalent binding.

Surfaces incorporating bioactive molecules by physical  
adsorption or entrapment beneath the blood-contacting  
20 surface exhibit a significant degree of thrombo-resistance.  
However, depletion of the bioactive molecules into the  
blood environment causes the surface to rapidly lose its  
thrombo-resistant character. Entrained molecules diffuse  
to the surface which, along with physically adsorbed  
25 bioactives, are then "leached" from the surface into the  
blood plasma by mechanical and chemical mechanisms.

Similarly, electrostatically or ionically bound  
molecules are subject to partitioning and ion exchange  
between the blood-contacting surface and the electrolyte-  
30 rich plasma resulting in depletion. Covalently bound  
bioactive molecules resist depletion sufficiently to offer  
a potentially "long term" thrombo-resistant effect.

Numerous studies of covalent attachment of different  
biomolecules are available. These studies generally  
35 involve the covalent attachment of a single bioactive

1 molecule, usually heparin, designed to counteract one  
aspect of the blood-material incompatibility reactions.  
Most studies have focused on covalently binding heparin to  
5 a blood-contacting surface. Heparin is the most effective  
anticoagulant in clinical use today. It is a highly  
sulfonated mucopolysaccharide containing a number of  
charged functional groups. Heparin enhances the  
inactivation of thrombin by antithrombin III, thereby  
10 inhibiting the conversion of fibrinogen to fibrin.

Most prior attempts to covalently bind heparin to a  
blood-contacting surface have severely decreased the  
activity of heparin. For example, heparin coupled to a  
blood-contacting surface through one of its carboxyl groups  
15 may lose up to 90% of its activity. Other systems,  
claiming covalent attachment of heparin, are actually  
heparin covalently bound to a coupling molecule which is  
subsequently ionically bound to the substrate.

Additional problems are encountered when the blood-  
20 contacting surface must also be gas permeable. Siloxane  
polymers are of particular interest in blood gas exchange  
devices because siloxane polymers not only possess certain  
inherent thrombo-resistant properties, but siloxane  
polymers also are gas permeable. However, siloxane  
25 polymers are relatively inert and pose a significant  
obstacle in modifying the surface in order to become more  
thrombo-resistant.

From the foregoing, it will be appreciated that what  
is needed in the art are thrombo-resistant compositions and  
30 methods which do not inhibit the gas permeability of the  
blood-contacting surface. Especially needed are methods  
for conferring thrombo-resistance to siloxane polymers.

It would be another important advancement in the art  
to provide gas permeable thrombo-resistant compositions and  
35 methods in which a bioactive molecule, such as heparin, is

1 covalently bound to the gas permeable blood-contacting surface, thereby eliminating elution of the bioactive molecule into the blood plasma.

5 It would be a further advancement in the art to provide gas permeable thrombo-resistant compositions and methods in which the bioactive molecules retain their activity after immobilization on the gas permeable blood-contacting surface.

10 Such gas permeable thrombo-resistant compositions and methods are disclosed and claimed herein.

#### BRIEF SUMMARY OF THE INVENTION

15 The present invention is directed to gas permeable thrombo-resistant coatings for use with gas permeable biomedical devices and implants. A quantity of at least one bioactive molecule selected to counteract a specific blood-material incompatibility reaction is preferably immobilized onto the gas permeable polymeric surface of the device which contacts the blood.

20 Siloxane is the presently preferred substrate surface (that is, to which bioactive molecules are bonded), because the substrate itself is initially relatively thrombo-resistant. Moreover, siloxane is gas permeable, thereby enabling the coatings of the present invention to be used in a variety of gas permeable applications.

25 In order to overcome the inertness of the siloxane surface, functional groups, preferably amine groups, are introduced onto the siloxane surface. Amine functionalities are preferably introduced onto the siloxane surface by plasma etching with ammonia gas. It is also possible to introduce amine functionalities onto the siloxane surface by addition of ammonia gas during plasma polymerization of a siloxane monomer.

1

In one currently preferred embodiment of the present invention, the amine functional groups on the siloxane surface are reacted with an aqueous solution of poly(ethylene oxide) bis(glycidyl ether). Other poly(ethylene oxide) (hereinafter referred to as "PEO") derivatives which may be successfully used within the scope of the present invention are aqueous solutions of poly(ethylene oxide) bis(2-amino-1,4-benzoquinone). After such reaction occurs, the siloxane surface contains PEO chains coupled to the amine groups. The PEO spacer chains are presently preferred because the PEO tends to minimize protein adsorption.

The unbound terminal end groups on the PEO chains readily react with the amine groups found in many bioactive molecules. The desired bioactive molecule is covalently bonded to one end of the PEO chains in a reaction similar to the reaction which covalently bonds the other end of the PEO chain to the gas permeable siloxane surface.

Since the desired bioactive molecule is spaced away from the siloxane surface at one end of a long PEO chain, the bioactive molecule possesses an activity approaching the activity of the bioactive molecule in solution. Because of this mobility of the bioactive molecule near the blood-contacting surface of the polymer, the effectiveness of the bioactive molecule is substantially greater than the same bioactive molecule bound directly to the blood-contacting surface. At the same time, the serious risks associated with systemic anticoagulation therapy are avoided.

Typical bioactive molecules which may be immobilized on a gas permeable siloxane surface within the scope of the present invention include: heparin, ticlopidine, iloprost, prostaglandin E<sub>1</sub> (PGE<sub>1</sub>), streptokinase, urokinase, and plasmin.

35



1

Heparin inhibits the blood incompatibility reaction resulting in clotting and thromboemboli formation by interacting with antithrombin III and thrombin to inhibit the conversion of fibrinogen to fibrin.

5

Ticlopidine, prostaglandin E<sub>1</sub>, and synthetic prostaglandin analogues, such as iloprost, inhibit the activation of platelets either by minimizing aggregation or inhibiting activation and the release of the intracellular platelet activators. Each drug has a slightly different mode of action. Urokinase, streptokinase, and plasmin are serine proteases which lyse formed protein deposits and networks, which while not inhibiting thrombus formation, breakdown any formed fibrin.

10

15

The present invention is unique because it enables a gas permeable siloxane surface to be coated with one or more bioactive molecules covalently bound thereto.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

20

The present invention provides a thrombo-resistant coating for use with a gas permeable blood-contacting surface of a medical device or implant. While it will immediately be appreciated that the present invention is applicable to a wide variety of other medical devices and implants, the coatings of the present invention are particularly suited for use with blood gas exchange devices. In any blood gas exchange device it is critical to both minimize thrombus and emboli formation, while at the same time preserving the gas exchange capabilities of the device.

25

30

Accordingly, for purposes of illustration, the coatings of the present invention are discussed with respect to one such blood gas exchange device (as described in the above-identified U.S. Patent No. 4,850,958 entitled "Apparatus and Method for In Vivo Extrapulmonary Blood Gas

35

1 Exchange"); however, it is not intended that the invention  
is to be construed as limited for use on only such a  
device.

5

A. Bioactive Molecules

To minimize the thrombo-resistant properties of any  
blood-contacting surface within the scope of the present  
invention, a quantity of at least one bioactive molecule  
10 which counteracts a specific blood-material incompatibility  
reaction is immobilized or linked to the blood-contacting  
surface.

The bioactive molecule is selected to inhibit blood  
material incompatibility reactions such as: coagulation  
15 and thrombus formation; platelet destruction, injury,  
entrapment, aggregation, and activation; complement  
activation; lysis of fibrin; and protein adsorption.  
Table I provides a summary of the various bioactive  
molecules which may be used within the scope of the present  
20 invention to combat blood-material incompatibility  
reactions.

25

30

35

1

TABLE I

5	BLOOD INCOMPATIBILITY REACTION	BIOACTIVE SUBSTANCE	TYPE OF BIOACTIVITY
	Extrinsic coagulation pathway activation	Heparin	Interruption of the conversion of fibrinogen to fibrin
10	Platelet destruction and injury, adhesion, and aggregation analogues release,	Prostaglandin E <sub>1</sub> and synthetic prostaglandin	Inhibits platelet shape change, platelet factor  secretion and aggregation
15		Ticlopidine	Protects platelets and inhibits platelet aggregation
20	Fibrin Formation	Plasmin Urokinase Streptokinase	Lyses fibrin Converts plasmin- ogen to plasmin, general proteolytic enzyme.
25		TPA	Activates plasminogen
30	Complement activation	FUT-175	Inhibits C1 <sub>s</sub> , C1 <sub>s</sub> , thrombin, and kallikrein

30

35

1 Any of the various bioactive molecules immobilized  
onto the surface gives the blood-contacting surface a  
thrombo-resistant coating. The term "thrombo-resistant" is  
5 generally used herein to generically represent the action  
of inhibiting any of the blood incompatibility reactions  
discussed above. Thus, despite substantial surface contact  
with blood, thrombus formation on the surface of the  
medical device or implant (e.g., a blood gas exchange  
10 device) is inhibited or counteracted according to the  
compositions and methods within the scope of the present  
invention.

It will be appreciated that Table I lists only a few  
of the bioactive substances which inhibit the identified  
15 blood-material incompatibility reactions and that other  
bioactive substances may be used in accordance with the  
present invention to make a surface thrombo-resistant. As  
is discussed hereinafter, another important feature of the  
bioactive molecules used in the present invention is the  
20 availability of a primary amine (or other suitable  
functional groups) to react with the unbound functional end  
group on a molecule attached to the substrate surface.

#### B. Blood Gas Exchange Device

25 The blood gas exchange devices to which the present  
invention is particularly applicable include both sheet  
membrane and tubular membrane oxygenators. Numerous  
oxygenators of these types are well known in the prior art.

For purposes of illustration, one blood gas exchange  
30 device to which the present invention is applicable  
includes a dual lumen tube containing two coaxial lumens.  
The outer lumen opens into an airtight proximal chamber to  
which the proximal ends of a plurality of elongated gas  
permeable tubes are attached. The inner lumen extends past  
35 the outer lumen and passes among the gas permeable tubes.

1 Both the inner lumen and the distal ends of gas permeable tubes open into an airtight distal chamber.

5 The device is inserted into the patient's venae cavae through an incision made in either the common femoral vein or the internal jugular vein. The gas permeable tubes are crimped in order to maintain the tubes in a spaced relation one from another so that the blood may flow freely between and around the tubes, thereby enhancing the blood surface  
10 contact with the gas permeable tubes.

One of either the inner or outer lumens is connected to a source of oxygen-rich gas. The other lumen is connected to an exhaust tube or other means for allowing the gas to flow out of the device. The oxygen-rich gas  
15 flows through the gas permeable tubes. As venous blood flows around the gas permeable tubes, oxygen passes from the tubes into the blood, thereby causing blood oxygenation, and carbon dioxide passes from the blood into the tubes and out of the body.

20 One of the primary goals of a blood gas exchange device (whether or not it has the specific configuration discussed above) is to maximize the gas transfer surface area in contact with the blood. Unfortunately, as the surface area of a foreign device in contact with blood  
25 increases, the risk of triggering a host of blood-material incompatibility reactions also increases.

Traditionally, as mentioned above, when a large quantity of blood contacts a foreign surface, systemic anticoagulants or thrombolytic agents are administered.  
30 Extreme care must be taken when administering any anticoagulants or thrombolytic agents to avoid the potential risk of serious hemorrhage both internally and externally. Thus, it is important that the blood-contacting surface of a blood gas exchange device is both  
35 gas permeable and thrombo-resistant. For these reasons,

1 when the present invention is used with a blood gas  
exchange device, the blood-contacting surface is preferably  
constructed of a thin siloxane polymer.

5

C. Obtaining a Gas Permeable Siloxane Surface

In the blood-gas exchange device of the present  
invention, microporous hollow fibers coated with a plasma-  
polymerized siloxane are used as the substrate. The term  
10 "plasma" refers to a thermodynamically non-equilibrium  
state. The energized electrons in the field can interact  
with the organic monomer or gases which produce mainly free  
radicals and ions. Any object in the field is subject to  
a negative charge of its surface. Ions and free radicals  
15 will impact the object's surface and under certain  
conditions a "plasma" thin film will form on the surface.

Two opposing processes occur simultaneously during  
plasma discharge. In general, it can be said that the  
generation of free radicals in the vapor phase lead to the  
20 formation of thin films. However, at high power of field  
strength, ions are generally responsible for ablation or  
"etching" of the surface. Generally at very low gas or  
monomer flow rates there is little polymer deposition and  
the deposition rate decreases with increasing discharge  
25 power. At higher flow rates, the deposition increases  
(linearly), but reaches a maximum with increasing discharge  
power and then ablation becomes more predominant.

The amount and relative position of polymer deposition  
is influenced by at least three geometric factors:  
30 (1) location of the electrode and distribution of charge;  
(2) monomer flow; and (3) substrate position within the  
reactor relative to the glow region. In the case of hollow  
fibers which are pulled continuously through the plasma  
chamber, the influence of the substrate position is

35

1 averaged over the length of the fibers. This is the  
currently preferred polymer deposition arrangement.

5 The population of energetic species that contribute to  
the direct formation of plasma polymer is not directly or  
uniquely related to the power input into the system. The  
intensity of a non-polymer forming plasma (i.e., plasma  
etching) is dependent on the combined factors of pressure  
and discharge power as well as on other factors of the  
10 discharge system such as distance between electrodes,  
surface area of electrodes, and total volume of the  
reactor.

Various parameters have been used to describe the  
energy input of plasma polymerization such as current  
15 density, current and voltage, or wattage. These parameters  
may have varying degrees of applicability to an inductively  
or capacitively coupled Radio Frequency ("RF") discharge  
system. However, such parameters are insufficient to  
describe the change in total volume of plasma and the  
20 plasma polymerization that takes place in the volume,  
although certain correlations can be found between the  
deposition rates and these parameters, but only for a given  
set of experimental conditions.

An important feature of the present invention,  
25 particularly for use with a blood oxygenator, is the  
creation of a smooth, continuous (pin-hole free) thin  
coating (less than 1 micron thick) over the pores of the  
hollow fiber. The thickness of this coating can be  
determined gravimetrically, and the continuity of the  
30 coating can be determined by the permeability. These  
factors, along with the chemical composition (i.e., carbon,  
silicone, oxygen, nitrogen percentages, determined by ESCA)  
are some of the values which change as plasma parameters  
are modified.

1

The chemical composition of the plasma coating affects the gas permeability. For example, as the cross-link density increases, the permeability decreases. Factors which affect the cross-link density include: pressure, power, flow rate, and position within the reactor. Gas permeability is also influenced by the plasma deposition thickness and the completeness of coverage of the pores.

5 The pressure, temperature, gas flow rates, exposure time, power, and other parameters in a plasma process are highly interdependent and highly dependent upon the size and geometry of the plasma chamber. The power per unit area is an important parameter in reproducibly controlling the chemical structure of the resulting polymer. However, since plasma polymerization and etching procedures and techniques are well known, a detailed discussion of each of the process parameters is not provided herein.

15 Plasma may be generated by a number of methods including combustion, flames, electric discharge, controlled nuclear reactions and shocks. The most obvious and commonly used is the electric discharge. Radio frequency ("RF") or microwave discharge are mainly used for polymerization reactions. For the commercial RF generators, the frequency is dictated by the Federal Communications Commission and is set at 13.56 MHz.

25 One currently preferred plasma machine used for the deposition of the siloxane membrane consists of a central bell jar with four peripheral vacuum chambers attached via glow zone pyrex tubing approximately 24 inches long. The RF discharge is coupled capacitively through two pair of copper electrodes on each arm. Therefore, each arm has two (2) glow zones.

30 The microporous hollow fiber substrate is pulled through from feed spools in the peripheral chambers through a system of pulleys such that the fiber passes through the

35



1 glow tubes more than once is taken up on spools in the  
central bell jar. The vacuum, RF power, monomer flow rate,  
and fiber speed are all computer controlled.

5 The currently preferred operating parameters are to  
expose the polypropylene microporous hollow fiber to a  
siloxane monomer having a mass flow rate of about 12  
 $\mu$ moles/second/arm at an absolute pressure of about 65  
mtorr. The fiber is pulled through each arm at a speed of  
10 about 3.2 cm/sec. A radio frequency of 13.56 MHz at about  
17 watts/arm is applied to the fiber.

The above conditions produce a cross-linked siloxane  
membrane on the polypropylene microporous hollow fiber on  
the order of about 0.5 to about 1.0 microns in thickness.  
15 When 1,3-divinyltetramethyl disiloxane is the siloxane  
monomer, the membrane has been found to have an oxygen  
permeability ranging from about  $0.37 \times 10^{-4}$  cm<sup>3</sup>/sec·cm<sup>2</sup>·cm Hg  
to about  $3.4 \times 10^{-4}$  cm<sup>3</sup>/sec·cm<sup>2</sup>·cm Hg and a carbon dioxide  
permeability ranging from  $0.8 \times 10^{-4}$  cm<sup>3</sup>/sec·cm<sup>2</sup>·cm Hg to  
20 about  $5.0 \times 10^{-4}$  cm<sup>3</sup>/sec·cm<sup>2</sup>·cm Hg. The permselectivity  
(ratio of permeabilities) of the membrane is in the range  
from about 2.5 to about 4.0.

When tetramethyl disiloxane is the siloxane monomer,  
the membrane has been found to have an oxygen permeability  
25 ranging from about  $0.9 \times 10^{-4}$  cm<sup>3</sup>/sec·cm<sup>2</sup>·cm Hg to about  $1.9$   
 $\times 10^{-4}$  cm<sup>3</sup>/sec·cm<sup>2</sup>·cm Hg and a carbon dioxide permeability  
ranging from about  $3.5 \times 10^{-4}$  cm<sup>3</sup>/sec·cm<sup>2</sup>·cm Hg to about  $5.2$   
 $\times 10^{-4}$  cm<sup>3</sup>/sec·cm<sup>2</sup>·cm Hg.

It will be appreciated that there are other methods  
30 for producing suitable siloxane coated hollow fibers.  
Nevertheless, the foregoing discussion is included to  
provide one skilled in the art with an understanding of one  
preferred method of producing suitable siloxane coated  
hollow fibers and typical parameters of such fibers.

1

D. Linking the Bioactive Molecules onto the Blood  
Contacting Surface

5 For purposes of illustration, reference will be made  
to "linking" or "immobilizing" bioactive molecules on the  
blood-contacting substrate surface of a blood gas exchange  
device. It will be readily appreciated that the principles  
and teachings of the present invention are generally  
10 applicable to most other medical devices and implants which  
contact blood and have a problem with thrombus and emboli  
formation.

Moreover, it will be appreciated that the term  
"immobilized" is being used in the sense that the bioactive  
molecules are covalently linked or "tethered" to a specific  
15 portion of the polymer substrate vis-a-vis free floating in  
the blood. Therefore, even though the bioactive molecules  
may not be directly attached to the blood-contacting  
surface (as discussed in greater detail below), the  
bioactive molecules are closely associated to the surface  
20 through a linkage such that the blood components contact  
the bioactive molecules as they come proximate to the  
blood-contacting surface.

Most of the bioactive molecules described above are  
capable of being immobilized to the blood-contacting  
25 surface of the blood gas exchange device through PEO  
coupling molecules. PEO is the preferred coupling  
molecule, because PEO itself functions to minimize protein  
adsorption. This property of PEO is believed to be due in  
part to PEO's unique hydrophobic and hydrophilic  
30 characteristics.

Because the blood-contacting surface of the blood-gas  
exchange device is preferably constructed of siloxane, the  
inherent inertness of the siloxane polymer minimizes  
thrombus formation. However, this same inherent inertness

35

1 of the siloxane significantly complicates the method of  
immobilizing the bioactive molecules to the surface.

To overcome the inertness of the siloxane, functional  
5 groups are introduced on the siloxane surface. These  
functional groups provide distinct and predictable sites  
for reaction with PEO. The PEO chains are then coupled to  
the blood-contacting surface through the functional groups.  
In the currently preferred embodiment of the present  
10 invention, amine groups are introduced onto the siloxane  
surface.

#### 1. Introduction of Amine Groups by Plasma Etching

One proposed method for introducing amine groups on  
15 the siloxane surface within the scope of the present  
invention involves plasma etching with ammonia gas. In the  
blood-gas exchange device of the present invention,  
microporous hollow fibers coated with a plasma-polymerized  
siloxane, described above, are used as the substrate.  
20 These fibers are subjected to additional plasma exposure in  
the presence of ammonia gas.

One plasma chamber used for plasma etching within the  
scope of the present invention has a volume of about 20,000  
cm<sup>3</sup> and capacitively coupled plate-type electrodes. The  
25 siloxane plasma-coated fibers, having a surface area of  
about 2,100 cm<sup>2</sup>, are exposed to ammonia having a flow rate  
in the range of from about 100 micromoles per second to  
about 300 micromoles per second, at an absolute pressure in  
the range from about 100 millitorr to about 200 mtorr. The  
30 exposure time ranges from about thirty (30) seconds to  
about fifteen minutes. The currently preferred exposure  
time is in the range from about 10 minutes to about 15  
minutes. A radio frequency of 13.56 MHz in the range from  
about 20 watts to about 250 watts generates sufficient

1 energy to break the molecular bonds of both the ammonia gas and the siloxane surface.

It will be appreciated by those skilled in the art that in a differently configured plasma chamber, the ammonia flow rate, power, chamber pressure, and exposure time may be outside the ranges of that set forth for the embodiment discussed above. Nevertheless, current experimental testing suggests that the power should relate to the monomer or gas flow rate such that  $W/FM$  is in the range from 30-50 megajoules/Kg, where W is the discharge power in joules per second, F is the mass flow rate in moles per second, and M is the molecular weight of a gas (g/mole). However, this value ( $W/FM$ ) does not take into consideration the power density which is determined by the volume of the plasma chamber. Because the minimum wattage necessary for the plasma polymer of a given monomer differs significantly from that of another monomer at a given pressure, it becomes immediately obvious that W, wattage per square centimeter, or current density alone is not sufficient to describe the conditions of plasma polymerization. Hence, the flow rate, power, and pressure may well be outside of the ranges given.

In light of these stoichiometric relationships, those skilled in the art can readily determine relationships between the flow rate, the pressure, and the exposure times of the siloxane surface to the ammonia.

Ammonia derivatives, existing as free radicals and ions react with each other and with the siloxane surface, thereby introducing amine functionalities onto the siloxane surface. Analysis by electron spectroscopy for chemical analysis ("ESCA") establishes that nitrogen in the form of amine functionalities can be introduced onto the surface on the order of from about three (3) to about seven (7) total atomic percent. ESCA measurements of about three total

1 atomic percent have been found to result in a satisfactory end product. Other polymers not as inert as siloxanes are capable of incorporating much higher amounts of nitrogen.

5 It should be noted that ESCA analyzes only the top 50-100 angstroms of a surface. Analysis of bulk structure below the sampling depth is not possible with ESCA. In addition, the atomic percent reported by ESCA is for the entire volume analyzed (*i.e.*, the top 50-100 angstroms).  
10 Thus, 3% nitrogen detected does not correspond with 3% of the surface atoms being nitrogen. Because of the bulk contribution to the ESCA signal, the actual percent nitrogen atoms on the surface would be significantly greater than 3%.

15 Nevertheless, ESCA does establish the existence of significant amounts of nitrogen at or near the surface. Moreover, analysis of percent nitrogen provides a valuable approximation for the number of free amines on the surface. The quantity of amines bound to the surface directly  
20 affects the coupling efficiency of the PEO or bioactive molecules. Thus, the more amine groups, the more PEO coupling sites.

From the foregoing, it will be appreciated that the parameters associated with ammonia etching are highly  
25 interdependent and dependent upon the specific plasma chamber. The following examples illustrate this interdependence. One skilled in the art would appreciate that the parameters described in the following examples can be modified when using a different sized plasma chamber.

30

#### EXAMPLE 1

Amine groups were introduced onto the surface of siloxane-coated hollow fibers within the scope of the present invention by plasma etching in the presence of  
35 ammonia. A plurality of microporous hollow fibers

1 incorporated into a fully formed intravenous extrapulmonary  
blood oxygenator were used as the substrate. The fibers  
were coated with plasma-polymerized siloxane.

5 The siloxane coated hollow fibers forming the  
oxygenator were subjected to plasma exposure in the  
presence of ammonia gas. The entire oxygenator was placed  
in a plasma chamber. The dimensions of the plasma chamber  
10 were fifteen inches long, twelve inches wide and five  
inches high. The electrodes were in the form of two  
parallel plates capacitively coupled in the chamber. The  
oxygenator was subjected to plasma exposure by introducing  
ammonia gas into the plasma chamber at the flow rate of 190  
15 micromoles per second at 170 mtorr absolute pressure. The  
hollow fibers were exposed to 180 watts at a radio  
frequency of 13.56 MHz for fifteen minutes.

According to ESCA analysis, nitrogen in the form of  
amine functionalities was introduced onto the surface on  
the order of three total atomic percent. As discussed  
20 hereinafter, this amount of nitrogen provides sufficient  
amine reaction sites for attachment of the PEO and the  
multifunctional bioactive molecules.

#### EXAMPLE 2

25 Amine groups were introduced onto the surface of a  
siloxane-coated hollow fibers according to the procedure of  
Example 1, except that fiber sheets, instead of a fully  
formed oxygenator, are placed in racks between the  
electrodes. Utilizing the procedures of Example 2,  
30 nitrogen in the form of amine functionalities was  
introduced onto the surface as analyzed by ESCA on the  
order of six total atomic percent.

Additional examples of introducing amine  
functionalities by ammonia etching are presented in

1  
 2  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35


compending patent application Serial No. 07/215,014,  
 Examples 1-8 which are incorporated by reference.

## 2. Introduction of Amine Groups by Plasma Polymerization

Another method for introducing the amine functionalities onto the blood-contacting surface of the siloxane polymer is to introduce the amine groups during the siloxane polymerization itself. This process, known as plasma polymerization or glow discharge polymerization, is achieved by introducing a siloxane monomer vapor and ammonia gas simultaneously in the presence of the plasma. The same type of tubular chamber used for plasma deposition of siloxane may be used for plasma polymerization of siloxane in the presence of ammonia gas.

## 3. Amine Functionalities on the Siloxane Surface

Both ammonia etching and plasma polymerization with ammonia result in amine incorporation into or onto the siloxane polymer. ESCA analysis of the resulting surface demonstrates the existence of Si-H bonds, C-N bonds, amine (NH<sub>2</sub>) groups, and carbonyl (C=O) groups. In addition, the surface likely includes reactive radicals (e.g., •CH<sub>2</sub> and •NH). While the exact surface structure resulting from these reaction processes is not known, the resulting surface structure is believed to be a combination of a number of possible bond and group configurations including:





5 R may be H or OH.

The degree of cross-linking (i.e., the number of bonds formed from methyl radicals on adjacent polymer chains reacting together to form an ethylene unit between chains) is totally dependent upon the reaction parameters. Any polymerization performed using plasma results in a "plasma polymer." The structure of a plasma polymer is significantly different from those resulting from other known polymerization mechanisms; these plasma polymers are by nature "ill-defined."

It will be appreciated that an important aspect of the present invention is the incorporation of amine functionalities (which are available for reaction with PEO) on the blood-contacting surface. Hence, other plasma reaction processes which introduce amine functionalities onto the surface are useful as a part of the present invention.

For example, another possible process for introducing amine functionalities on the blood-contacting surface would be to coat the surface with siloxane monomer in the plasma, and then introduce another polymerizable gas which contains amine groups. One potentially suitable amine-containing polymerizable gas is allylamine.

In addition, depending on the type of siloxane monomer used to form the siloxane surface, nitrogen gas is a suitable alternative to ammonia gas in both the plasma etching and plasma polymerization processes described above. Nitrogen gas initially introduces both amine groups and nitrogen radicals onto the siloxane surface, but upon exposure to water vapor, the nitrogen radicals quickly



1 quench to form amine groups. Because nitrogen is less  
expensive than ammonia, the use of nitrogen gas can  
significantly reduce the costs associated with the plasma  
5 process described above.

Although the foregoing discussion has focused on the  
incorporation of amine groups onto the siloxane surface, it  
will be appreciated that the principles within the scope of  
the present invention may be readily adapted to incorporate  
10 other reactive functional groups onto the siloxane surface.

Thus, an important aspect of the invention is the  
incorporation of any reactive functional group such as  
hydroxyl, carbonyl, or carboxylic groups onto the siloxane  
surface. These functional groups would provide a chemical  
15 "handle" on the otherwise inert siloxane surface to which  
PEO and bioactive molecules may be bound.

The surfaces which emerge from the plasma in any of  
the processes discussed above are highly reactive. While  
exact molecular analysis is difficult, the surfaces likely  
20 contain some radicals which are available for reacting with  
almost any species containing double bonds which come into  
contact with the siloxane surface.

#### 4. Reaction of Amine Functionalities with PEO.

25 Immediately upon removal from the plasma, the surfaces  
of the hollow fibers may be reacted with the terminal end  
groups of unbranched PEO. The PEO functions as an extended  
flexible spacer to tether bioactive molecules away from,  
but in close proximity to, the siloxane surface, thereby  
30 avoiding problems of steric hindrance of adjacent bioactive  
molecules which may then be coupled to the siloxane  
surface. Moreover, as discussed above, the PEO itself also  
assists in minimizing protein adsorption on the siloxane  
surface.

1

A PEO solution is prepared by dissolving poly(ethylene oxide) bis(glycidyl ether) (commonly known as "PEO diglycidyl ether," or "polyoxyethylene diglycidyl ether") in water. The PEO must be in excess to minimize "looping" of the PEO by both reactive ends coupling to the amine groups on the surface. Typical PEO concentrations are in the range from about 5% to about 36%, and preferably about 5% to about 10%.

5

10

Poly(ethylene oxide) bis(glycidyl ether) of any molecular weight may be used. However, for maximum protein resistance, the range should be from about 1500 to about 6000 and preferably in the range from about 3000 to about 4000. It has been found that PEO within this molecular weight range minimizes the protein adsorption and maximizes repulsion of platelets and other formed elements from the surface. There is a balance between chain length and stability as well. Longer chains are more susceptible to chain scission. Shorter PEO chains are less flexible, which reduces their protein-resistant properties.

15

20

25

30

Many terminal reactive groups on PEO may be used depending upon the functionality on the siloxane to which coupling is desired. In addition to epoxide terminated PEO, other suitable terminal groups include 2-(aminoalkyl)-1,4-benzoquinone, bis-(aminediacetic acid), bis-(aminediacetic acid ethyl ester), bis-(aminediacetic acid methyl ester), bis-(amineacetic acid), bis-(3,5-dioxomorpholine), bis-succinyl-monoamide(monophthalimide), and bis-phosphate(pyrophosphate). In any event, only those PEO chains with two or more reactive functional groups would be available for coupling to a surface and to a bioactive molecule.


35

In the case of epoxide-terminated PEO, the percent epoxide within the PEO varies depending upon the manufacturer and can vary from about 10% to greater than

1 75% epoxide. The percentage epoxide directly affects the  
coupling efficiency. Therefore, if 100% of all PEO chains  
contain terminal epoxide groups, theoretically all could  
5 bind not only to the surface but also be available for  
binding bioactive molecules.

The plasma-coated fibers of the blood gas exchange  
device are allowed to sit in the PEO solution, with  
agitation, for about twelve hours. It has been found that  
10 the amount of PEO coupling (as determined by ESCA) does not  
significantly increase after fifteen (15) hours. In  
addition, increasing the concentration of PEO (to about 36  
weight percent in the solvent) does not significantly  
increase the amount of coupling over the same time  
15 interval. The temperature of the PEO solution is  
preferably maintained at ambient temperature, in the range  
from about 20°C to about 30°C.

After removal from the PEO solution, the coated hollow  
fibers are rinsed with purified water to remove any unbound  
20 PEO. The epoxide groups located at the terminal ends of  
the PEO chains have reacted with the amine groups located  
on the siloxane surface as shown below:



30 Upon analysis by ESCA, the surface typically contains ether  
carbon of the carbon 1s spectrum in the range from about  
20% to about 50% of the total carbon signal. These carbon

1 atoms on the surface are attributed to PEO attachment to the siloxane surface of the siloxane-coated substrate.

Due to the large excess of PEO used and reaction  
5 conditions, only one end of the PEO chain is bound to an amine group on the siloxane surface. As a result, each PEO chain contains an unreacted epoxide group at its unbound end. The epoxide effectively reacts with the electron-rich amine nitrogen because epoxide is a highly strained three-  
10 member ring. It also contains an electron depleted carbon atom. The epoxide efficiency is due mainly to the strained ring.

In addition, any carbon radicals ( $\cdot\text{CH}_2$ ) remaining on the surface following plasma polymerization would not be  
15 expected to react with the epoxide groups and would continue to be reactive.

It has been found that the PEO chains may also be suitably terminated with isocyanate functionalities if done under nonaqueous conditions. Other PEO derivatives which  
20 should produce suitable results are identified above.

Despite the process used to incorporate the amine functionalities onto the siloxane surface, the PEO can readily react with the amine groups to attach the PEO to the siloxane surface.

25

#### 5. PEO Reaction With Bioactive Molecules.

According to the present invention, the unbound end of the PEO is reacted with a quantity of at least one bioactive molecule to covalently bond the bioactive  
30 molecules to the PEO which is itself bonded to the gas permeable siloxane surface. An important preferred embodiment of the present invention is to bind the bioactive molecules to the PEO linkages in order to result in a polymer surface having thrombo-resistant properties.

35

1

Such bonding of bioactive molecules to the PEO on the siloxane surface of a blood gas exchange device occurs when the device is placed in a solution containing the desired bioactive molecule. One currently preferred bioactive molecule solution is a 5% (wt/vol) heparin/water solution.

5

The heparin solution is prepared by dissolving heparin in 100 ml phosphate buffered saline (having a pH in the range of from about 7.1 to about 7.5, preferably a pH of about 7.4) resulting in a concentration in the range from about 500 to about 1500 USP units per milliliter. Preferably, the heparin concentration is about 850 USP units per milliliter.

10

The PEO/siloxane surface is preferably soaked in the heparin solution for about 12 hours with agitation. The heparin solution is maintained at ambient temperature in the range from about 20°C to about 30°C. Upon removal from the solution, the surface is washed with purified water, air dried, and sterilized with ethylene oxide.

15

The heparin surface concentration of samples prepared in this manner are found to contain approximately 0.025  $\mu\text{g}/\text{cm}^2$  of heparin by radio isotope methods. These surfaces are also capable of specifically binding antithrombin III demonstrating their activity. The gas permeability of formed intravenous blood oxygenator devices treated in this way remains significantly greater during operation than untreated microporous hollow fibers or siloxane coated fibers without the PEO and heparin.

20


25

It has been found that the heparin, or other bioactive molecules, are coupled to the epoxide groups of the PEO chains through any primary amines available on the bioactive molecule. While the exact mechanism is not known, it is theorized that the heparin, urokinase, plasmin, and other bioactive pharmaceuticals are coupled to the PEO as shown below.


30

35

1



10 "NH<sub>2</sub>-DRUG" refers to an amine-containing bioactive molecule. The bioactive molecules are coupled to 2-(aminoalkyl)-1,4-benzoquinone-terminated PEO chains through a similar mechanism shown below.



30 Thrombogenicity tests were performed utilizing the "Acute Canine Intra-Arterial Thrombogenicity Assay" procedure described in Mortensen et al., "A Practical Screening Test for Thrombogenicity of Intraarterial Catheters -- Preliminary Report," Artificial Organs, Vol.

35

1 2, Supp., pp. 76-80, 1978, which is incorporated herein by  
reference. Thrombogenicity testing results have indicated  
that the heparin molecules are present and active on the  
5 surface. Small bundles of treated hollow fibers were  
implanted into the carotid and femoral arteries of large  
dogs for a period of 30 minutes. The amount of adherent  
thrombus and that expelled from the artery following  
withdrawal of the bundle was weighed and compared with the  
10 controls.

Siloxane coated surfaces with PEO and heparin  
demonstrated an index of 0.016 while control surfaces  
exhibit an index of 0.060. Statistically significant  
differences were determined with 95% confidence limits.  
15 Other commercially available surfaces with and without  
heparin were also tested and found to produce indices  
ranging from 0.002 to 0.250.

The long term efficacy of siloxane coated surfaces  
with PEO and heparin covalently bound thereto as described  
20 above was tested in the Chronic Ovine Intra-Venous  
Thrombogenicity Assay. Briefly, this assay involves  
implantation of approximately 20 cm catheter samples into  
the right and left femoral and jugular veins of 70 kg sheep  
through multiple venotomies. The catheters are left in  
25 place for a period of 15 days with no systemic heparin  
administered after surgery. The animal is permitted normal  
activity for a period of 15 days after which heparin is  
administered prior to sacrificing the animal. The veins  
are surgically removed and opened to expose the catheter  
30 lying in place. The appearance and distribution of the  
thrombus present is documented photographically. The  
thrombogenicity score is developed from determination of  
the thickness of the clot on the catheter, the amount of  
adherent clot to the vein wall, the amount of free clot in  
35 the vein and the percent occlusion of the vein by thrombus.

1 In addition, the catheters are rated by gross thrombus  
weight for comparison. Each catheter is tested in three  
animals with a control surface. All data are normalized  
5 by analysis of covariance to correct for animal to animal  
variations. Commercially available catheters with and  
without other heparin coatings are included in the  
analyses.

The geometric mean thrombus weights ranged from 544.6  
10 mg to 1754.3 mg for all catheter samples tested. Devices  
having a siloxane coated surface with PEO and heparin  
covalently bound thereto within the scope of the present  
invention produced a mean thrombus weight of 544.6 mg,  
superior to all other catheters tested. This demonstrates  
15 that other commercial coatings involving ionically bound  
heparin were not effective in the inhibition of thrombosis  
over the 15 day testing period. The observed differences  
are significant within 90% confidence limits. The amount  
of thrombus formed on the commercial devices was  
20 considerably greater than the amount of thrombus formed on  
devices having a thrombo-resistant coating within the scope  
of the present invention.

The data indicate that while some catheters tested  
were heparin coated, they did not perform significantly  
25 better in prevention of thrombus formation than other non-  
heparinized coatings, and they did not perform as well as  
devices having a siloxane coated surface with PEO and  
heparin covalently bound thereto. This follows from a  
theoretical argument that ionically bound heparin will  
30 leach from a surface and become depleted within a very  
short time. The thrombo-resistant coating within the scope  
of the present invention, which covalently binds heparin to  
the siloxane surface through a PEO linkage, was the only  
heparinized coating catheter to maintain heparin activity  
35 over the 15 day testing period.



1 Not only should the thrombo-resistant coatings within  
the scope of the present invention inhibit thrombus  
formation, but also maintain suitable gas permeability over  
5 time. Intravenous blood oxygenator devices containing  
microporous hollow fibers coated with a siloxane membrane  
and treated with PEO and heparin within the scope of the  
present invention were implanted in the vena cavae of  
sheep. The oxygenator devices maintained suitable gas  
10 transfer over a period of nineteen (19) days with less than  
10% loss of efficiency.

#### E. Summary

15 In summary, the thrombo-resistant compositions and  
methods disclosed herein are capable of counteracting  
blood-material incompatibility reactions without inhibiting  
the gas permeability of the blood-contacting surface. This  
is accomplished by immobilizing a quantity of at least one  
20 bioactive molecule which counteracts a specific blood  
material incompatibility reaction to the blood-contacting  
siloxane surface through individual poly(ethylene oxide)  
spacer chains. Because the bioactive molecules are  
tethered away from the blood-contacting surface, the  
molecules avoid problems of steric hindrance and possess an  
25 activity approaching the activity in solution. In  
addition, the bioactive molecules are covalently bound to  
the blood-contacting surface, thereby eliminating leaching  
of the bioactive molecules into the blood plasma and  
prolonging the effectiveness of the thrombo-resistant  
30 composition.

The present invention may be embodied in other  
specific forms without departing from its spirit or  
essential characteristics. The described embodiments are  
to be considered in all respects only as illustrative and  
35 not restrictive. The scope of the invention is, therefore,

1 indicated by the appended claims rather than by the  
foregoing description. All changes which come within the  
meaning and range of equivalency of the claims are to be  
5 embraced within their scope.

What is claimed is:

10

15

20

25

30

35

1

1. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood, the method comprising the steps of:

5

(a) obtaining a gas permeable material having a gas permeable siloxane surface onto which a plurality of amine functional groups have been bonded;

10

(b) reacting the amine functional groups on the siloxane surface with poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine functional groups on the siloxane surface, thereby resulting in a product having single poly(ethylene oxide) chains which are bonded to corresponding single amine functional groups, said product being gas permeable;

15

(c) reacting the product of step (b) with at least one bioactive molecule capable of counteracting at least one blood-material incompatibility reaction such that a single bioactive molecule is correspondingly coupled to a single poly(ethylene oxide) chain, thereby resulting in a gas permeable siloxane surface to which are attached, by a poly(ethylene oxide) chain, a plurality of the at least one bioactive molecule which react with blood components which come in proximity to the siloxane surface of the gas permeable material in order to resist at least one blood-material incompatibility reaction.

20

25

30

2. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood as defined in claim 1, wherein the step of obtaining a gas permeable material having a siloxane surface onto which a plurality of amine functional groups have been bonded comprises the steps of:

35

1

introducing ammonia gas within a plasma chamber capable of performing plasma etching;

5

exposing the ammonia gas to a radio frequency of sufficient power to create a plasma; and

exposing the siloxane surface to the ammonia plasma for sufficient time to introduce amine functional groups onto the siloxane surface.

10

3. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood as defined in claim 2, further comprising the step of obtaining a microporous hollow fiber having a siloxane surface thereon.

15

4. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood as defined in Claim 1, wherein the poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine functional groups comprises poly(ethylene oxide) bis(glycidyl ether).

20

5. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood as defined in Claim 1, wherein the poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine functional groups comprises poly(ethylene oxide) 2-(aminoalkyl)-1,4-benzoquinone.

25

30

6. A method for producing a thrombo-resistant coating for use on gas permeable surfaces which contact blood as defined in claim 1, wherein the poly(ethylene oxide) chains have a molecular weight in the range from about 1500 to 6000.

35

1  
7. A method for producing a thrombo-resistant  
coating for use on gas permeable surfaces which contact  
blood as defined in claim 1, wherein the product of step  
5 (b) is reacted with a solution of at least one bioactive  
molecule capable of resisting at least one of the following  
blood-material incompatibility reactions: extrinsic  
coagulation pathway activation, platelet destruction and  
injury, platelet adhesion activation, platelet aggregation,  
10 thrombus formation, complement activation, contact system  
activation, and fibrinolytic system activation.

8. A method for producing a thrombo-resistant  
coating for use on gas permeable surfaces which contact  
15 blood as defined in claim 1, wherein the product of step  
(b) is reacted with heparin.

9. A method for producing a thrombo-resistant  
coating for use on gas permeable surfaces which contact  
20 blood as defined in claim 1, wherein the product of step  
(b) is reacted with at least one bioactive molecule  
selected from the group including heparin, urokinase,  
plasmin, and ticlopidine.

25 10. A method for producing a thrombo-resistant  
coating for use on gas permeable surfaces which contact  
blood as defined in claim 1, wherein the product of step  
(b) is reacted with at least one bioactive molecule  
selected from the group including heparin, urokinase, and  
30 prostaglandin E<sub>1</sub>.

11. A method for producing a thrombo-resistant  
coating for use on gas permeable surfaces which contact  
blood as defined in claim 1, wherein the product of step  
35 (b) is reacted with at least one bioactive molecule

1 selected from the group including heparin, plasmin, and  
ticlopidine.

5 12. A method for producing a thrombo-resistant  
coating for use on gas permeable surfaces which contact  
blood as defined in claim 1, wherein the product of step  
(b) is reacted with at least one bioactive molecule  
selected from the group including heparin, urokinase,  
10 plasmin, prostaglandin E<sub>1</sub>, and ticlopidine.

13. A method for producing a thrombo-resistant  
coating for use on gas permeable surfaces which contact  
blood, the method comprising the steps of:

15 (a) obtaining a gas permeable material having a  
siloxane surface;

(b) introducing ammonia gas within a plasma  
chamber capable of performing plasma etching;

20 (c) exposing the ammonia gas to a radio  
frequency of sufficient power to create a plasma;

(d) exposing the siloxane surface to the ammonia  
plasma for sufficient time to introduce amine  
functional groups onto the siloxane surface, thereby  
resulting in a product having a plurality of amine  
functional groups bonded onto the siloxane surface;

25 (e) reacting the product of step (d) with a  
solution having a plurality of poly(ethylene oxide)  
spacer chains, having the following general formula



30 wherein R<sub>1</sub> and R<sub>2</sub> are suitable functional groups  
capable of reacting with the amine functional groups  
on the siloxane surface; and

(f) reacting the product of step (e) with a  
solution of at least one bioactive molecule capable of  
35 counteracting specific blood-material incompatibility

1 reactions such that a single bioactive molecule is  
correspondingly coupled to a single poly(ethylene  
oxide) spacer chain, thereby resulting in a siloxane  
5 surface to which are attached, by a poly(ethylene  
oxide) chain, a plurality of the at least one  
bioactive molecules which react with blood components  
which come in proximity to the surface of the material  
in order to resist at least one blood-material  
10 incompatibility reaction.

14. A method for producing a thrombo-resistant  
coating for use on gas permeable surfaces which contact  
blood as defined in claim 13, wherein  $R_1$  and  $R_2$  comprise  
15 glycidyl ether.

15. A method for producing a thrombo-resistant  
coating for use on gas permeable surfaces which contact  
blood as defined in claim 13, wherein  $R_1$  and  $R_2$  comprise 2-  
20 (aminoalkyl)-1,4-benzoquinone.

16. A method for producing a thrombo-resistant  
coating for use on gas permeable surfaces which contact  
blood as defined in claim 13, wherein the product of step  
25 (e) is reacted with heparin.

17. A method for producing a thrombo-resistant  
coating for use on gas permeable surfaces which contact  
blood as defined in claim 13, wherein the product of step  
30 (e) is reacted with a plurality of at least one bioactive  
molecule selected from the group including heparin,  
urokinase, plasmin, and ticlopidine.

18. A method for producing a thrombo-resistant  
35 coating for use on gas permeable surfaces which contact

1 blood as defined in claim 13, wherein the product of step  
(e) is reacted with a plurality of at least one bioactive  
molecule selected from the group including heparin,  
5 urokinase, plasmin, ticlopidine, and prostaglandin E<sub>1</sub>.

19. A thrombo-resistant composition for use on gas permeable surfaces which contact blood comprising:

10 a gas permeable material having a siloxane surface onto which a plurality of at least one bioactive molecule are covalently bonded, said at least one bioactive molecule counteracting at least one specific blood-material incompatibility reaction when the blood comes into proximity of the surface of  
15 the material; and

a plurality of poly(ethylene oxide) chains covalently bonded to the bioactive molecules and covalently bonded to the siloxane surface such that a single bioactive molecule is correspondingly coupled  
20 to a single poly(ethylene oxide) chain which in turn is bonded to the gas permeable siloxane surface.

20. A thrombo-resistant composition for use on gas permeable surfaces which contact blood as defined in claim  
25 19, wherein the at least one bioactive molecule is capable of resisting at least one of the following blood material incompatibility reactions: extrinsic coagulation pathway activation, platelet destruction and injury, platelet adhesion, platelet aggregation, thrombus formation, and  
30 complement activation.

21. A thrombo-resistant composition for use on gas permeable surfaces which contact blood as defined in claim  
19, wherein the at least one bioactive molecule is heparin.



1

22. A thrombo-resistant composition for use on gas permeable surfaces which contact blood as defined in claim 19, wherein the at least one bioactive molecule is selected from the group including heparin, urokinase, plasmin, ticlopidine, and prostaglandin E<sub>1</sub>.

10

23. A thrombo-resistant composition for use on gas permeable surfaces which contact blood, the composition being made by a process comprising the steps of:

(a) obtaining a gas permeable material having a siloxane surface onto which a plurality of amine functional groups have been bonded;

15

(b) reacting the amine functional groups on the siloxane surface with poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine functional groups on the siloxane surface such that a single poly(ethylene oxide) chain is bonded to a corresponding single amine functional group; and

20

(c) reacting the product of step (b) with heparin such that a single heparin molecule is covalently bonded to a single poly(ethylene oxide) chain, thereby resulting in a siloxane surface to which are attached, by a poly(ethylene oxide) chain, a plurality of heparin molecules capable of reacting with blood components which come in proximity to the siloxane surface of the material in order to resist at least one blood-material incompatibility reactions.

25  
30

24. A thrombo-resistant composition for use on gas permeable surfaces which contact blood as defined in Claim 23, wherein the poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine

35

1 functional groups comprises poly(ethylene oxide)  
bis(glycidyl ether).


5 25. A thrombo-resistant composition for use on gas  
permeable surfaces which contact blood as defined in Claim  
23, wherein the poly(ethylene oxide) chains terminated with  
functional groups capable of reacting with the amine  
functional groups comprises poly(ethylene oxide) 2-  
10 (aminoalkyl)-1,4-benzoquinone.

26. A thrombo-resistant composition comprising a  
plurality of compounds having the formula



15 wherein X is a siloxane surface; and wherein  $R_1$  are  $R_2$  are  
the residue resulting from a reaction between a  
poly(ethylene oxide) terminal group capable of reacting  
with an amine and capable of reacting with a bioactive  
molecule, respectively; and wherein Y is a bioactive  
20 molecule capable of counteracting a specific blood material  
incompatibility reaction.

27. A thrombo-resistant composition as defined in  
claim 26, wherein  $R_1$  is



28. A thrombo-resistant composition as defined in  
claim 26, wherein Y is heparin.

30

29. A thrombo-resistant composition as defined in  
claim 26, wherein Y is heparin, ticlopidine, or urokinase.

35

1

30. A thrombo-resistant composition as defined in claim 26, wherein Y is heparin, prostaglandin E<sub>1</sub>, plasmin, urokinase, or tissue plasminogen activator.

5

31. A thrombo-resistant composition as defined in claim 26, wherein Y is heparin, ticlopidine, plasmin, urokinase, tissue plasminogen activator, or FUT-175.

10

32. A thrombo-resistant composition as defined in claim 26, wherein Y is capable of resisting either extrinsic coagulation pathway activation, platelet destruction and injury, platelet adhesion, platelet aggregation, thrombus formation, or complement activation.

15

33. An apparatus for effecting extrapulmonary blood gas exchange comprising:

a plurality of gas permeable tubes, each tube having a proximal end and a distal end, said gas permeable tubes being coated with a thrombo-resistant composition comprising a plurality of compounds having the formula



25

wherein X is a siloxane surface on a gas permeable tube; and wherein R<sub>1</sub> are R<sub>2</sub> are the residue resulting from a reaction between a poly(ethylene oxide) terminal group capable of reacting with an amine and capable of reacting with a bioactive molecule, respectively; and wherein Y is a bioactive molecule capable of counteracting at least one blood-material incompatibility reaction;

30

35

a dual lumen coaxial tube comprising an inner lumen and an outer lumen, said inner lumen extending between the proximal and distal ends of the gas permeable tubes and said outer lumen terminating

1

adjacent to the proximal ends of the gas permeable tubes and the inner lumen terminating adjacent to the distal ends of the gas permeable tubes, such that the gas permeable tubes are in gaseous communication with both the inner lumen and the outer lumen;

5

10

means for introducing oxygen from the inner lumen into the distal ends of the gas permeable tubes whereby blood in contact with the gas permeable tubes receives oxygen from the gas permeable tubes and releases carbon dioxide gas to the gas permeable tubes; and

15

means for collecting carbon dioxide at the proximal ends of the gas permeable tubes and introducing said carbon dioxide into the outer lumen for removal therethrough.

20

34. An apparatus for effecting extrapulmonary blood gas exchange as defined in claim 33, wherein the at least one bioactive molecule comprises heparin.

25

30

35

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/02415

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC (5): A01N 1/00; A61M 1/14, 37/00; A61L 33/00; C08J 7/04		
U.S. CL. 523/112; 422/48; 604/4, 26, 43, 49		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
U.S.	523/112; 422/48; 604/4, 26, 43, 49	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	US, A, 4,349,467 (WILLIAMS ET AL) 14 SEPTEMBER 1982; See the entire document.	1-32
<u>X</u> Y	S.W. KIM ET AL, "Nonthrombogenic Bioactive Surfaces", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Volume 516, (1987) pages 116-130. See the entire document.	<u>1-32</u> 33-34
<u>X</u> Y	HOLLAHAN ET AL, "Attachment of Amino Groups to Polymer Surfaces by Radiofrequency Plasmas": JOURNAL OF APPLIED POLYMER SCIENCE VOL. 13, pages 807-816 (1969). See the entire document.	<u>1-32</u> 33-34
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
21 JUNE 1991		31 JUL 1991
International Searching Authority		Signature of Authorized Officer
ISA/US		for Thomas McDonald, Jr.